TY  - JOUR

T1  - RO4 COST-EFFECTIVENESS ANALYSIS OF RFVIIIFC, PEGYLATED RFVIII, AND EMICIZUMAB FOR THE PROPHYLACTIC TREATMENT OF SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN THE UNITED STATES

JO  - Value in Health

PY  - 2019/05/01

AU  - Li N

AU  - Bullement A

AU  - McMordie S

AU  - Hatswell AJ

AU  - Wilson K

ED  - 

DO  - DOI: 10.1016/j.jval.2019.04.1898

PB  - Elsevier BV

VL  - 22

SP  - S389

EP  - S389

Y2  - 2024/12/26

ER  -